Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 6, 2013, Pages 583-592

  Chung, Yu Heng ^a   Lee, Yen Chieh ^a   Chang, Chia Hsuin ^b,c,d   Lin, Min Shung ^a   Lin, Jou Wei ^c,d   Lai, Mei Shu ^b  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cohort studies; HMG CoA; Pharmacoepidemiology; Renal dialysis; Renal insufficiency; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION;

CHOLESTEROL, LDL; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE CLAIM REVIEW; KIDNEY FUNCTION TESTS; MALE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX;

EID: 84878791450     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3433     Document Type: Article

References (38)

1. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65, 000 patients. J Am Coll Cardiol 2008; 52: 1769-1781.
2. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010; 55: 1266-1273.
3. Arca M, Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs 2007; 67(Suppl 1): 29-42.
4. Kalaitzidis RG, Elisaf MS. The role of statins in chronic kidney disease. Am J Nephrol 2011; 34: 195-202.
5. Navaneethan SD, Hegbrant J, Strippoli GF. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 146-152.
6. Wanner C, Krane V, Marz W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004; 27: 259-266.
7. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
8. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.
9. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112: 171-178.
10. Kimura K, Shimano H, Yokote K, Urashima M, Teramoto T. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb 2010; 17: 601-609.
11. Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother 2010; 11: 817-828.
12. Kuwabara M, Kubo T, Bando K, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the progression of renal dysfunction in Japanese hypertensive patients. Geriatr Gerontol Int 2010; 10: 219-224.
13. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009; 206: 512-517.
14. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J 2007; 1: 8-14.
15. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336: 645-651.
16. Atthobari J, Brantsma AH, Gansevoort RT, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006; 21: 3106-3114.
17. Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Intern Med 2011; 50: 1273-1278.
18. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340: c2197.
19. Verhulst A, Geryl H, D'Haese P. No evidence for statin-induced proteinuria in healthy volunteers as assessed by proteomic analysis. J Biomed Biotechnol 2011; 2011: 456076.
20. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-124.
21. Kostapanos MS, Milionis HJ, Saougos VG, et al. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. J Cardiovasc Pharmacol Ther 2007; 12: 292-297.
22. Alagona P, Jr. Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evid 2010; 5: 91-105.
23. Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med 2008; 148: 258-267.
24. National Health Insurance Research Database. http://w3.nhri.org.tw/nhird/en/Background.html [18 April 2012, date last accessed].
25. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005; 14: 465-476.
26. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005; 330: 960-962.
27. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291-303.
28. Riegersperger M, Sunder-Plassmann G. How to prevent progression to end stage renal disease. J Ren Care 2007; 33: 105-107.
29. Szummer K, Lundman P, Jacobson SH, et al. Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 2011; 79: 997-1004.
30. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-1613.
31. Sharyo S, Yokota-Ikeda N, Mori M, et al. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int 2008; 74: 577-584.
32. Vidt DG, Ridker PM, Monyak JT, Schreiber MJ, Cressman MD. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Clin Ther 2011; 33: 717-725.
33. Chauhan V, Vaid M. Dyslipidemia in chronic kidney disease: managing a high-risk combination. Postgrad Med 2009; 121: 54-61.
34. Nanchen D, Pletcher MJ, Cornuz J, et al. Public health impact of statin prescribing strategies based on JUPITER. Prev Med 2011; 52: 159-163.
35. Campese VM, Ku E, Bigazzi R, Bianchi S. Do HMG-CoA reductase inhibitors improve kidney function? The saga continues. J Nephrol 2011; 24: 550-553.
36. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton) 2010; 15(Suppl 2): 3-9.
37. McClellan W, Warnock DG, McClure L, et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol 2006; 17: 1710-1715.
38. Kim MC, Ahn Y, Jang SY, et al. Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction. Korean J Intern Med 2011; 26: 294-303.